TSMHT
BIO icon

Thurston Springer Miller Herd & Titak’s Bio-Rad Laboratories Class A BIO Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$487 – 1648
2025
Q1 		$487 Buy
+2
New +$602 ﹤0.01% 1579

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's BIO Position: Q2 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 2 shares — an estimated $487 sold.

Thurston Springer Miller Herd & Titak first reported a position in BIO in Q1 2025 and held it in 1 quarter. The position peaked at $487 in Q1 2025. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 2 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $487.
  • Thurston Springer Miller Herd & Titak first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's Bio-Rad Laboratories Class A position peaked at $487 in Q1 2025.
  • 384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2025, filed 7 Jul 2025.